Biogen (NASDAQ:BIIB) Given “Buy” Rating at Truist Financial

Biogen (NASDAQ:BIIB)‘s stock had its “buy” rating restated by analysts at Truist Financial in a research note issued to investors on Thursday, Benzinga reports. They presently have a $260.00 price objective on the biotechnology company’s stock, up from their prior price objective of $235.00. Truist Financial‘s price target points to a potential upside of 3.40% from the stock’s current price.

BIIB has been the topic of several other reports. Bank of America increased their target price on Biogen from $219.00 to $244.00 and gave the stock a “neutral” rating in a research report on Thursday, October 22nd. Stifel Nicolaus set a $242.00 price target on shares of Biogen in a report on Thursday, September 10th. Wedbush upped their price target on shares of Biogen from $212.00 to $225.00 and gave the stock a “neutral” rating in a research report on Thursday. Morgan Stanley upped their price target on shares of Biogen from $222.00 to $231.00 and gave the stock an “equal weight” rating in a research report on Thursday, July 30th. Finally, Guggenheim increased their price objective on shares of Biogen from $260.00 to $280.00 and gave the stock a “buy” rating in a report on Tuesday, July 21st. One research analyst has rated the stock with a Strong Buy rating, twenty-one have given a Buy rating, ten have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Biogen has a consensus rating of “Moderate Buy” and a consensus price target of $248.00.

Biogen Trading Up 3.0%

Shares of Biogen stock traded up $7.41 during trading hours on Thursday, hitting $251.46. The company’s stock had a trading volume of 202,122 shares, compared to its average volume of 1,211,260. The business has a fifty day moving average of $225.73 and a 200 day moving average of $200.39. The company has a quick ratio of 1.26, a current ratio of 1.87 and a debt-to-equity ratio of 0.39. Biogen has a 1-year low of $138.00 and a 1-year high of $258.78. The company has a market capitalization of $37.15 billion, a PE ratio of 44.60, a P/E/G ratio of 2.99 and a beta of 0.09.

Biogen (NASDAQ:BIIB) last announced its quarterly earnings results on Wednesday, October 28th. The biotechnology company reported $2.62 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.99 by $0.63. Biogen had a return on equity of 11.18% and a net margin of 8.32%. The business had revenue of $2.80 billion for the quarter, compared to the consensus estimate of $2.63 billion. During the same quarter last year, the business posted $4.81 EPS. The business’s revenue was up 10.6% on a year-over-year basis. As a group, equities analysts forecast that Biogen will post 12.29 EPS for the current year.

Hedge Funds Weigh In On Biogen

Institutional investors have recently made changes to their positions in the stock. Probity Advisors Inc. boosted its position in shares of Biogen by 3.6% during the third quarter. Probity Advisors Inc. now owns 1,183 shares of the biotechnology company’s stock valued at $267,000 after buying an additional 41 shares during the period. Forum Financial Management LP raised its holdings in shares of Biogen by 2.4% in the third quarter. Forum Financial Management LP now owns 1,936 shares of the biotechnology company’s stock worth $437,000 after buying an additional 46 shares during the period. Integrated Advisors Network LLC raised its holdings in shares of Biogen by 3.5% in the third quarter. Integrated Advisors Network LLC now owns 1,403 shares of the biotechnology company’s stock worth $317,000 after buying an additional 48 shares during the period. Wedbush Securities Inc. raised its holdings in shares of Biogen by 5.1% in the second quarter. Wedbush Securities Inc. now owns 1,164 shares of the biotechnology company’s stock worth $251,000 after buying an additional 56 shares during the period. Finally, Meeder Advisory Services Inc. lifted its stake in shares of Biogen by 1.2% during the 1st quarter. Meeder Advisory Services Inc. now owns 4,721 shares of the biotechnology company’s stock worth $866,000 after acquiring an additional 57 shares during the last quarter. Institutional investors own 87.93% of the company’s stock.

Key Headlines Impacting Biogen

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: Biogen reported adjusted third-quarter earnings of $2.62 per share, well above analyst expectations of roughly $1.99–$2.06, while revenue rose 10.6% year over year to $2.80 billion, also exceeding estimates. Biogen third-quarter earnings report
• Positive Sentiment: The newer growth portfolio continued to offset pressure on older multiple sclerosis products, with revenue increasing 49% to $1.26 billion. Rare-disease revenue rose 27% to $676 million, helped in part by the first full quarter of products acquired through Apellis. Biogen Q3 revenue and earnings update
• Positive Sentiment: Biogen raised the lower end of its 2026 adjusted EPS guidance to $12.20, producing a new range of $12.20 to $13.00. Needham and Baird subsequently raised their price targets to $290 and assigned bullish “buy” and “outperform” ratings, respectively. Analyst forecasts for Biogen
• Neutral Sentiment: Biogen plans to present additional Alzheimer’s disease data at CTAD 2026, including long-term CELIA study data for diranersen and extended real-world and clinical evidence for lecanemab. The presentations could provide future pipeline catalysts, but the data will not affect near-term earnings. Biogen CTAD 2026 announcement
• Negative Sentiment: Despite the adjusted-profit beat, Biogen posted a GAAP net loss of $20.6 million, or $0.14 per share, compared with a profit of $466.5 million a year earlier. The loss primarily reflected transaction-related expenses, including $284 million of acquired research and development costs tied largely to the RayThera acquisition. Biogen GAAP loss report
• Negative Sentiment: Barclays raised its price target to $230 but retained an “equal weight” rating, leaving its target below the current trading level. Unusually heavy put-option activity also indicated increased near-term hedging or bearish speculation. Barclays Biogen rating

Biogen Company Profile

Biogen Inc is a biotechnology company that discovers, develops and commercializes therapies for neurological and neurodegenerative diseases. Its areas of focus include multiple sclerosis, Alzheimer’s disease, spinal muscular atrophy, amyotrophic lateral sclerosis and other serious medical conditions.

The company’s portfolio includes multiple sclerosis treatments such as Tecfidera, Vumerity, Tysabri, Plegridy and Avonex, as well as Spinraza for spinal muscular atrophy. Biogen also markets Leqembi, an Alzheimer’s disease treatment developed in collaboration with Eisai, and works with partners to advance additional therapies and biosimilars.

Biogen was founded in 1978 and is headquartered in Cambridge, Massachusetts.